Relationship between tumor DNA methylation status and patient characteristics in african-american and european-american women with breast cancer

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Wang, Songping ^a   Dorsey, Tiffany H ^b   Terunuma, Atsushi ^b   Kittles, Rick A ^c   Ambs, Stefan ^b   Kwabi Addo, Bernard ^a  

^a HOWARD UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CADHERIN; CADHERIN 13; ESTROGEN RECEPTOR ALPHA; GENOMIC DNA; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; SECRETED FRIZZLED RELATED PROTEIN 1; UNCLASSIFIED DRUG; H CADHERIN; H-CADHERIN; MEMBRANE PROTEIN; RASSF1 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR, BETA2, HUMAN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT THERAPY; ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BREAST CANCER; CANCER TISSUE; CDH13 GENE; CLINICAL FEATURE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; ESR1 GENE; EUROPEAN AMERICAN; FEMALE; HIN1 GENE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LONG INTERSPERSED REPEAT; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; P16 GENE; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; RARBETA2 GENE; RASSF1A GENE; SFRP1 GENE; TUMOR SUPPRESSOR GENE; AGED; BREAST TUMOR; CAUCASIAN; GENETICS; MIDDLE AGED;

ADULT; AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CADHERINS; CPG ISLANDS; DNA METHYLATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MEMBRANE PROTEINS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RECEPTORS, RETINOIC ACID; TUMOR SUPPRESSOR PROTEINS;

EID: 84861712337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037928     Document Type: Article

References (42)

1. Amend K, Hicks D, Ambrosone CB, (2006) Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 66: 8327-8330.
2. American Cancer Society (2009) Breast Cancer Facts and Figures: 2009-2010 Atlanta, GA American Cancer Society.
3. Ries L, Eisner M, Kosary M, (2011) SEER cancer statistics review, 1973-1999 Bethesda (MD) National Cancer Institute; 2002.
4. Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, et al. (1994) Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 3: 127-135.
5. Cunningham JE, Butler WM, (2004) Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat 88: 161-176.
6. Li CI, Malone KE, Daling JR, (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163: 49-56.
7. O'Malley CD, Le GM, Glaser SL, Shema SJ, West DW, (2003) Socioeconomic status and breast carcinoma survival in four racial/ethnic groups: a population-based study. Cancer 97: 1303-1311.
8. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID, et al. (2007) Racial disparities in breast cancer outcome: insights into host-tumor interactions. Cancer 110: 1880-1888.
9. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
11. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
12. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, et al. (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68: 3108-3114.
13. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, et al. (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113: 357-370.
14. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, et al. (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97: 439-448.
15. Yu K, Lee CH, Tan PH, Tan P, (2004) Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 10: 5508-5517.
16. Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, et al. (2003) Breast cancer genetics in African Americans. Cancer 97: 236-245.
17. Rose DP, Royak-Schaler R, (2001) Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev 25: 16-31.
18. Weston A, Godbold JH, (1997) Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 105 (Suppl 4): 919-926.
19. Joe AK, Arber N, Bose S, Heitjan D, Zhang Y, et al. (2001) Cyclin D1 overexpression is more prevalent in non-Caucasian breast cancer. Anticancer Res 21: 3535-3539.
20. Bowen RL, Stebbing J, Jones LJ, (2006) A review of the ethnic differences in breast cancer. Pharmacogenomics 7: 935-942.
21. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, et al. (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66: 8297-8308.
22. Loo LW, Wang Y, Flynn EM, Lund MJ, Bowles EJ, et al. (2011) Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat 127: 297-308.
23. Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, et al. (2009) Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One 4: e4531.
24. Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, et al. (2004) Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res 10: 5998-6005.
25. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, et al. (2003) DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107: 970-975.
26. Lehmann U, Celikkaya G, Hasemeier B, Langer F, Kreipe H, (2002) Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 62: 6634-6638.
27. Tisserand P, Fouquet C, Barrois M, Gallou C, Dendale R, et al. (2003) Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1 linked tumors. Cancer Biol Ther 2: 559-563.
28. Mehrotra J, Ganpat MM, Kanaan Y, Fackler MJ, McVeigh M, et al. (2004) Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res 10: 2052-2057.
29. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, et al. (2010) Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 120: 3843-3854.
30. Shu J, Jelinek J, Chang H, Shen L, Qin T, et al. (2006) Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 66: 5077-5084.
31. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, et al. (2007) Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 13: 3796-3802.
32. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, et al. (2010) Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 16: 3539-3547.
33. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, et al. (2007) Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9: R57.
34. Konishi K, Shen L, Wang S, Meltzer SJ, Harpaz N, et al. (2007) Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology 132: 1254-1260.
35. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R, (2003) Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 35: 146-150.
36. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
37. Celebiler CA, Kilic Y, Saydam S, Canda T, Baskan Z, et al. (2009) Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer. Cancer Sci 100: 2341-2345.
38. Issa JP, (2002) Epigenetic variation and human disease. J Nutr 132: 2388S-2392S.
39. Chan TA, Glockner S, Yi JM, Chen W, Van NL, et al. (2008) Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 5: e114.
40. Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de VJ, et al. (2008) DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat 111: 429-437.
41. Wendt MK, Cooper AN, Dwinell MB, (2008) Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells. Oncogene 27: 1461-1471.
42. Selhub J, (2002) Folate, vitamin B12 and vitamin B6 and one carbon metabolism. J Nutr Health Aging 6: 39-42.